| Year |
Citation |
Score |
| 2023 |
Gicobi JK, Mao Z, DeFranco G, Hirdler JB, Li Y, Vianzon VV, Dellacecca ER, Hsu MA, Barham W, Yan Y, Mansfield AS, Lin Y, Wu X, Hitosugi T, Owen D, ... ... Dong H, et al. Salvage therapy expands highly cytotoxic and metabolically fit resilient CD8 T cells via ME1 up-regulation. Science Advances. 9: eadi2414. PMID 37967193 DOI: 10.1126/sciadv.adi2414 |
0.409 |
|
| 2023 |
Zheng J, Wang L, Zhao S, Zhang W, Chang Y, Bosco DB, Huang T, Dheer A, Gao S, Xu S, Ayasoufi K, Al-Kharboosh R, Qi F, Xie M, Johnson AJ, ... Dong H, et al. TREM2 mediates MHCII-associated CD4+ T cell response against gliomas. Neuro-Oncology. PMID 37941134 DOI: 10.1093/neuonc/noad214 |
0.364 |
|
| 2023 |
Zhong W, Lu Y, Han X, Yang J, Qin Z, Zhang W, Yu Z, Wu B, Liu S, Xu W, Zheng C, Schuchter LM, Karakousis GC, Mitchell TC, Amaravadi R, ... ... Dong H, et al. Upregulation of exosome secretion from tumor-associated macrophages plays a key role in the suppression of anti-tumor immunity. Cell Reports. 42: 113224. PMID 37805922 DOI: 10.1016/j.celrep.2023.113224 |
0.443 |
|
| 2023 |
Rodrigues Pessoa R, Zhang H, Zganjar A, Nabavizadeh R, Packiam VT, Lohse CM, Cheville JC, Pagliaro LC, Costello BA, Boorjian SA, Thompson RH, Lucien F, Dong H, Leibovich BC. Circulating antigen-primed cytotoxic T-cells in patients with renal tumors treated with surgery. Urologic Oncology. PMID 37414595 DOI: 10.1016/j.urolonc.2023.05.009 |
0.339 |
|
| 2023 |
Liu X, Aneas I, Sakabe N, Anderson RL, Billstrand C, Paz C, Kaur H, Furner B, Choi S, Prichina AY, Enninga EAL, Dong H, Murtha A, Crawford GE, Kessler JA, et al. Single cell profiling at the maternal-fetal interface reveals a deficiency of PD-L1 non-immune cells in human spontaneous preterm labor. Scientific Reports. 13: 7903. PMID 37193763 DOI: 10.1038/s41598-023-35051-5 |
0.34 |
|
| 2023 |
An Z, Hsu MA, Gicobi JK, Xu T, Harrington SM, Zhang H, Pavelko KD, Hirdler JB, Lohse CM, Nabavizadeh R, Pessoa RR, Sharma V, Thompson RH, Leibovich BC, Dong H, et al. A Novel PD-L1 Antibody Promotes Antitumor Function of Peripheral Cytotoxic Lymphocytes after Radical Nephrectomy in Patients with Renal Cell Carcinoma. Journal of Immunology (Baltimore, Md. : 1950). PMID 37163328 DOI: 10.4049/jimmunol.2200933 |
0.459 |
|
| 2023 |
Zheng J, Wang L, Zhao S, Zhang W, Chang Y, Dheer A, Gao S, Xu S, Ayasoufi K, Al-Kharboosh R, Xie M, Johnson AJ, Dong H, Qui Ones-Hinojosa A, Wu LJ. TREM2 mediates MHCII-associated CD4 T cell response against gliomas. Biorxiv : the Preprint Server For Biology. PMID 37066234 DOI: 10.1101/2023.04.05.535697 |
0.4 |
|
| 2023 |
Barham W, Hsu M, Liu X, Harrington SM, Hirdler JB, Gicobi JK, Zhu X, Zeng H, Pavelko KD, Yan Y, Mansfield AS, Dong H. A Novel Humanized PD-1/PD-L1 Mouse Model Permits Direct Comparison of Antitumor Immunity Generated by Food and Drug Administration-Approved PD-1 and PD-L1 Inhibitors. Immunohorizons. 7: 125-139. PMID 36656137 DOI: 10.4049/immunohorizons.2200054 |
0.41 |
|
| 2022 |
Gicobi JK, Dellacecca ER, Dong H. Resilient T-cell responses in patients with advanced cancers. International Journal of Hematology. PMID 35864292 DOI: 10.1007/s12185-022-03424-7 |
0.322 |
|
| 2022 |
Mahmoud AM, Frank I, Orme JJ, Lavoie RR, Thapa P, Costello BA, Cheville JC, Gupta S, Dong H, Lucien F. Evaluation of PD-L1 and B7-H3 expression as a predictor of response to adjuvant chemotherapy in bladder cancer. Bmc Urology. 22: 90. PMID 35751046 DOI: 10.1186/s12894-022-01044-1 |
0.431 |
|
| 2022 |
Friedman DJ, Kizerwetter M, Belmonte P, Rajcula M, Theodore K, Kim Lee HS, Shapiro MJ, Dong H, Shapiro VS. Cutting Edge: Enhanced Antitumor Immunity in ST8Sia6 Knockout Mice. Journal of Immunology (Baltimore, Md. : 1950). 208: 1845-1850. PMID 35379746 DOI: 10.4049/jimmunol.2101165 |
0.342 |
|
| 2022 |
Zhu M, Zhang H, Pedersen KS, Foster NR, Jaszewski BL, Liu X, Hirdler JB, An Z, Bekaii-Saab TS, Halfdanarson TR, Boland PM, Yan Y, Hubbard JH, Ma WW, Yoon HH, ... ... Dong H, et al. Understanding Suboptimal Response to Immune Checkpoint Inhibitors. Advanced Biology. e2101319. PMID 35343107 DOI: 10.1002/adbi.202101319 |
0.363 |
|
| 2022 |
Sun L, Wang Y, Wang X, Navarro-Corcuera A, Ilyas S, Jalan-Sakrikar N, Gan C, Tu X, Shi Y, Tu K, Liu Q, Lou Z, Dong H, Sharpe AH, Shah VH, et al. PD-L1 promotes myofibroblastic activation of hepatic stellate cells by distinct mechanisms selective for TGF-β receptor I versus II. Cell Reports. 38: 110349. PMID 35139382 DOI: 10.1016/j.celrep.2022.110349 |
0.331 |
|
| 2022 |
Zhang W, Zhong W, Wang B, Yang J, Yang J, Yu Z, Qin Z, Shi A, Xu W, Zheng C, Schuchter LM, Karakousis GC, Mitchell TC, Amaravadi R, Herlyn M, ... Dong H, et al. ICAM-1-mediated adhesion is a prerequisite for exosome-induced T cell suppression. Developmental Cell. PMID 35085484 DOI: 10.1016/j.devcel.2022.01.002 |
0.458 |
|
| 2021 |
Wen T, Barham W, Li Y, Zhang H, Gicobi JK, Hirdler JB, Liu X, Ham H, Peterson Martinez KE, Lucien F, Lavoie RR, Li H, Correia C, Monie DD, An Z, ... ... Dong H, et al. NKG7 is a T-cell intrinsic therapeutic target for improving antitumor cytotoxicity and cancer immunotherapy. Cancer Immunology Research. PMID 34911739 DOI: 10.1158/2326-6066.CIR-21-0539 |
0.476 |
|
| 2021 |
Lavoie RR, Gargollo PC, Ahmed ME, Kim Y, Baer E, Phelps DA, Charlesworth CM, Madden BJ, Wang L, Houghton PJ, Cheville J, Dong H, Granberg CF, Lucien F. Surfaceome Profiling of Rhabdomyosarcoma Reveals B7-H3 as a Mediator of Immune Evasion. Cancers. 13. PMID 34572755 DOI: 10.3390/cancers13184528 |
0.42 |
|
| 2021 |
Bansal A, Pandey MK, Barham W, Liu X, Harrington SM, Lucien F, Dong H, Park SS, DeGrado TR. Non-invasive immunoPET imaging of PD-L1 using anti-PD-L1-B11 in breast cancer and melanoma tumor model. Nuclear Medicine and Biology. 100: 4-11. PMID 34119742 DOI: 10.1016/j.nucmedbio.2021.05.004 |
0.346 |
|
| 2021 |
Wang Y, Sinha S, Wellik LE, Secreto CR, Rech KL, Call TG, Parikh SA, Kenderian SS, Muchtar E, Hayman SR, Koehler AB, Van Dyke DL, Leis JF, Slager SL, Dong H, et al. Distinct immune signatures in chronic lymphocytic leukemia and Richter syndrome. Blood Cancer Journal. 11: 86. PMID 33972504 DOI: 10.1038/s41408-021-00477-5 |
0.358 |
|
| 2021 |
Chen C, Li S, Xue J, Qi M, Liu X, Huang Y, Hu J, Dong H, Ling K. PD-L1 tumor-intrinsic signaling and its therapeutic implication in triple-negative breast cancer. Jci Insight. 6. PMID 33884962 DOI: 10.1172/jci.insight.131458 |
0.352 |
|
| 2020 |
Barham W, Guo R, Park SS, Herrmann J, Dong H, Yan Y. Case Report: Simultaneous Hyperprogression and Fulminant Myocarditis in a Patient With Advanced Melanoma Following Treatment With Immune Checkpoint Inhibitor Therapy. Frontiers in Immunology. 11: 561083. PMID 33603731 DOI: 10.3389/fimmu.2020.561083 |
0.468 |
|
| 2020 |
Breen WG, Leventakos K, Dong H, Merrell KW. Radiation and immunotherapy: emerging mechanisms of synergy. Journal of Thoracic Disease. 12: 7011-7023. PMID 33282406 DOI: 10.21037/Jtd-2019-Cptn-07 |
0.438 |
|
| 2020 |
Orme JJ, Enninga EAL, Lucien-Matteoni F, Dale H, Burgstaler E, Harrington SM, Ball MK, Mansfield AS, Park SS, Block MS, Markovic SN, Yan Y, Dong H, Dronca RS, Winters JL. Therapeutic plasma exchange clears circulating soluble PD-L1 and PD-L1-positive extracellular vesicles. Journal For Immunotherapy of Cancer. 8. PMID 32817395 DOI: 10.1136/Jitc-2020-001113 |
0.404 |
|
| 2020 |
Loeuillard E, Yang J, Buckarma E, Wang J, Liu Y, Conboy CB, Pavelko KD, Li Y, O'Brien D, Wang C, Graham RP, Smoot RL, Dong H, Rizvi S. Targeting tumor-associated macrophages and granulocytic-myeloid-derived suppressor cells augments pd-1 blockade in cholangiocarcinoma. The Journal of Clinical Investigation. PMID 32663198 DOI: 10.1172/Jci137110 |
0.485 |
|
| 2020 |
Yu J, Qin B, Moyer AM, Nowsheen S, Tu X, Dong H, Boughey JC, Goetz MP, Weinshilboum R, Lou Z, Wang L. Author Correction: Regulation of sister chromatid cohesion by nuclear PD-L1. Cell Research. PMID 32636455 DOI: 10.1038/S41422-020-0365-Y |
0.359 |
|
| 2020 |
Vera Aguilera J, Paludo J, McWilliams RR, Zhang H, Li Y, Kumar AB, Failing J, Kottschade LA, Block MS, Markovic SN, Dong H, Dronca RS, Yan Y. Chemo-immunotherapy combination after PD-1 inhibitor failure improves clinical outcomes in metastatic melanoma patients. Melanoma Research. PMID 32404734 DOI: 10.1200/Jco.2018.36.15_Suppl.9558 |
0.485 |
|
| 2020 |
Orme JJ, Jazieh KA, Xie T, Harrington S, Liu X, Ball M, Madden B, Charlesworth MC, Azam TU, Lucien F, Wootla B, Li Y, Villasboas JC, Mansfield AS, Dronca RS, ... Dong H, et al. ADAM10 and ADAM17 cleave PD-L1 to mediate PD-(L)1 inhibitor resistance. Oncoimmunology. 9: 1744980. PMID 32363112 DOI: 10.1080/2162402X.2020.1744980 |
0.467 |
|
| 2020 |
Yu J, Qin B, Moyer AM, Nowsheen S, Tu X, Dong H, Boughey JC, Goetz MP, Weinshilboum R, Lou Z, Wang L. Regulation of sister chromatid cohesion by nuclear PD-L1. Cell Research. PMID 32350394 DOI: 10.1038/S41422-020-0315-8 |
0.493 |
|
| 2020 |
Johnson RMG, Wen T, Dong H. Bidirectional signals of PD-L1 in T cells that fraternize with cancer cells. Nature Immunology. PMID 32152507 DOI: 10.1038/S41590-020-0599-3 |
0.53 |
|
| 2020 |
Himes BT, Peterson TE, de Mooij T, Garcia MLMC, Jung MY, Uhm S, Yan D, Tyson J, Li HJL, Parney D, Abukhadra M, Gustafson MP, Dietz AB, Johnson AJ, Dong H, et al. The role of extracellular vesicles and PD-L1 in glioblastoma-mediated immunosuppressive monocyte induction. Neuro-Oncology. PMID 32080744 DOI: 10.1093/Neuonc/Noaa029 |
0.447 |
|
| 2020 |
Li C, Zhu B, Son YM, Wang Z, Jiang L, Xiang M, Ye Z, Beckermann KE, Wu Y, Jenkins JW, Siska PJ, Vincent BG, Prakash YS, Peikert T, Edelson BT, ... ... Dong H, et al. The Transcription Factor Bhlhe40 Programs Mitochondrial Regulation of Resident CD8 T Cell Fitness and Functionality. Immunity. 52: 201-202. PMID 31940270 DOI: 10.1016/J.Immuni.2019.12.008 |
0.36 |
|
| 2020 |
Packiam VT, Bhindi B, Zhang H, Lohse CM, Shah PH, Tsivian M, Pagliaro LC, Costello BA, Thompson RH, Boorjian SA, Cheville J, Dong H, Leibovich BC. The impact of surgical resection on circulating tumor-reactive cytotoxic T cells for patients with renal tumors. Journal of Clinical Oncology. 38: 725-725. DOI: 10.1200/Jco.2020.38.6_Suppl.725 |
0.398 |
|
| 2020 |
Zhu M, Zhang H, Foster NR, Dong H, Bekaii-Saab TS, Jaszewski BL, Boland PM, Overman MJ, Pedersen K, McWilliams RR, Academic. Abstract 4467: Bim and CX3CR1/granzyme B in circulating CD8+ T cells are predictive biomarkers for PD-1 blockade therapy Immunology. DOI: 10.1158/1538-7445.Am2020-4467 |
0.532 |
|
| 2019 |
Eckel-Passow JE, Ho TH, Serie DJ, Cheville JC, Houston Thompson R, Costello BA, Dong H, Kwon ED, Leibovich BC, Parker AS. Concordance of PD-1 and PD-L1 (B7-H1) in paired primary and metastatic clear cell renal cell carcinoma. Cancer Medicine. PMID 31829518 DOI: 10.1002/Cam4.2769 |
0.504 |
|
| 2019 |
Li C, Zhu B, Son YM, Wang Z, Jiang L, Xiang M, Ye Z, Beckermann KE, Wu Y, Jenkins JW, Siska PJ, Vincent BG, Prakash YS, Peikert T, Edelson BT, ... ... Dong H, et al. The Transcription Factor Bhlhe40 Programs Mitochondrial Regulation of Resident CD8 T Cell Fitness and Functionality. Immunity. 51: 491-507.e7. PMID 31533057 DOI: 10.1016/J.Immuni.2019.08.013 |
0.506 |
|
| 2019 |
Feng D, Qin B, Pal K, Sun L, Dutta S, Dong H, Liu X, Mukhopadhyay D, Huang S, Sinicrope FA. BRAF-induced, tumor intrinsic PD-L1 can regulate chemotherapy-induced apoptosis in human colon cancer cells and in tumor xenografts. Oncogene. PMID 31406255 DOI: 10.1038/S41388-019-0919-Y |
0.475 |
|
| 2019 |
Sideras K, de Man RA, Harrington SM, Polak WG, Zhou G, Schutz HM, Pedroza-Gonzalez A, Biermann K, Mancham S, Hansen BE, Bart Takkenberg R, van Vuuren AJ, Pan Q, Ijzermans JNM, Sleijfer S, ... ... Dong H, et al. Circulating levels of PD-L1 and Galectin-9 are associated with patient survival in surgically treated Hepatocellular Carcinoma independent of their intra-tumoral expression levels. Scientific Reports. 9: 10677. PMID 31337865 DOI: 10.1038/s41598-019-47235-z |
0.322 |
|
| 2019 |
Tu X, Qin B, Zhang Y, Zhang C, Kahila M, Nowsheen S, Yin P, Yuan J, Pei H, Li H, Yu J, Song Z, Zhou Q, Zhao F, Liu J, ... ... Dong H, et al. PD-L1 (B7-H1) Competes with the RNA Exosome to Regulate the DNA Damage Response and Can Be Targeted to Sensitize to Radiation or Chemotherapy. Molecular Cell. PMID 31053471 DOI: 10.1016/J.Molcel.2019.04.005 |
0.434 |
|
| 2019 |
Duma N, Abdel-Ghani A, Yadav S, Hoversten KP, Reed CT, Sitek AN, Enninga EAL, Paludo J, Aguilera JV, Leventakos K, Lou Y, Kottschade LA, Dong H, Mansfield AS, Manochakian R, et al. Sex Differences in Tolerability to Anti-Programmed Cell Death Protein 1 Therapy in Patients with Metastatic Melanoma and Non-Small Cell Lung Cancer: Are We All Equal? The Oncologist. PMID 31036771 DOI: 10.1634/Theoncologist.2019-0094 |
0.407 |
|
| 2019 |
Wu X, Li Y, Liu X, Chen C, Harrington SM, Cao S, Xie T, Pham T, Mansfield AS, Yan Y, Kwon ED, Wang L, Ling K, Dong H. Corrigendum to "Targeting B7-H1 (PD-L1) sensitizes cancer cells to chemotherapy" [Heliyon 4 (12) (December 2018) e01039]. Heliyon. 5: e01309. PMID 30937406 DOI: 10.1016/j.heliyon.2019.e01309 |
0.335 |
|
| 2019 |
Jalali S, Price-Troska T, Bothun C, Villasboas J, Kim HJ, Yang ZZ, Novak AJ, Dong H, Ansell SM. Reverse signaling via PD-L1 supports malignant cell growth and survival in classical Hodgkin lymphoma. Blood Cancer Journal. 9: 22. PMID 30783096 DOI: 10.1038/S41408-019-0185-9 |
0.446 |
|
| 2019 |
Aguilera JV, Erskine CL, Suman VJ, Paludo J, McWilliams RR, Kottschade LA, Yan Y, Dronca RS, Dong H, Markovic S, Block MS. IL-12p40 and MIP3a to predict clinical responses to anti-PD-1 therapy in patients with metastatic melanoma. Journal of Clinical Oncology. 37: 9535-9535. DOI: 10.1200/Jco.2019.37.15_Suppl.9535 |
0.399 |
|
| 2019 |
Orme J, Villasboas J, Dong H. Tumor ADAM10/ADAM17-Mediated PD-L1 Loss May Predict Poor Outcomes in Diffuse Large B Cell Lymphoma Blood. 134: 4120-4120. DOI: 10.1182/Blood-2019-124189 |
0.461 |
|
| 2019 |
Yan Y, Dong H, Dronca R, Markovic S. Abstract PR11: CX3CR1+CD8+ T-cells are responsible to the clinical benefit of chemoimmunotherapy in metastatic melanoma patients after disease progression on PD-1 blockade Cancer Immunology Research. 7. DOI: 10.1158/2326-6074.Cricimteatiaacr18-Pr11 |
0.496 |
|
| 2019 |
Orme JJ, Jazieh K, Harrington S, Ball M, Azam TU, Liu X(, Xie T, Mansfield A, Dronca RS, Dong H. Abstract A210: Tumor-associated ADAM10 and ADAM17 produce soluble PD-L1 (sPD-L1, sB7-H1) and affect downstream tumor immunity – A resistance mechanism to PD-1 checkpoint blockade in melanoma Cancer Immunology Research. 7. DOI: 10.1158/2326-6074.Cricimteatiaacr18-A210 |
0.535 |
|
| 2019 |
Feng D, Pal K, Mukhopadhyay D, Liu X, Dong H, Huang S, Sinicrope FA. Abstract 705: Tumor intrinsic PD-L1 is mediated byBRAFV600Eand can regulate drug-induced apoptosis in human colon cancer Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-705 |
0.412 |
|
| 2019 |
Zhang H, Liu X, Cao S, Chen L, Harrington S, Li Y, Mansfield A, Park S, Yan Y, Dronca R, Dong H. Abstract 4080: Expansion of CX3CR1+ cytotoxic CD8+ T cells provides a rationale for IL-15 in combination cancer therapy with PD-1 antibody Cancer Research. 79: 4080-4080. DOI: 10.1158/1538-7445.Am2019-4080 |
0.501 |
|
| 2019 |
Himes B, Peterson T, Tyson J, Lee H, deMooij T, Cumba-Garcia L, Jung M, Gustafson M, Dietz A, Johnson A, Dong H, Maus R, Svetomir M, Lucien-Matteoni F, Yan D, et al. Immu-36. The Role Of Pd-L1 In Glioblastoma-Derived Extracellular Vesicles In The Induction Of Immunosuppressive Monocytes Neuro-Oncology. 21. DOI: 10.1093/Neuonc/Noz175.528 |
0.402 |
|
| 2019 |
Loeuillard E, Bronk S, Dong H, Rizvi S. 853 – Cholangiocarcinoma (CCA) Derived Extracellular Vesicles Reprogram Hepatic Macrophages to a Pd-L1+ PRO-Tumor Phenotype Gastroenterology. 156. DOI: 10.1016/S0016-5085(19)37262-2 |
0.415 |
|
| 2019 |
Mutter RW, Tu X, Qin B, Zhang Y, Zhang C, Kahila MM, Nowsheen S, Yin P, Yuan J, Li H, Yu J, Zhou Q, Zhao F, Liu J, Dong H, et al. PD-L1 is an RNA Binding Protein That Regulates the Expression of DNA Damage Response Genes and Can be Targeted to Sensitize Cancer to Radiation International Journal of Radiation Oncology Biology Physics. 105. DOI: 10.1016/J.Ijrobp.2019.06.559 |
0.35 |
|
| 2018 |
Wu X, Li Y, Liu X, Chen C, Harrington SM, Cao S, Xie T, Orzechowski A, Pham T, Mansfield AS, Yan Y, Kwon ED, Wang L, Ling K, Dong H. Targeting B7-H1 (PD-L1) sensitizes cancer cells to chemotherapy. Heliyon. 4: e01039. PMID 30603685 DOI: 10.1016/J.Heliyon.2018.E01039 |
0.496 |
|
| 2018 |
Jin X, Ding D, Yan Y, Li H, Wang B, Ma L, Ye Z, Ma T, Wu Q, Rodrigues DN, Kohli M, Jimenez R, Wang L, Goodrich DW, de Bono J, ... Dong H, et al. Phosphorylated RB Promotes Cancer Immunity by Inhibiting NF-κB Activation and PD-L1 Expression. Molecular Cell. PMID 30527665 DOI: 10.1016/J.Molcel.2018.10.034 |
0.49 |
|
| 2018 |
Liang Y, Tang H, Guo J, Qiu X, Yang Z, Ren Z, Sun Z, Bian Y, Xu L, Xu H, Shen J, Han Y, Dong H, Peng H, Fu YX. Targeting IFNα to tumor by anti-PD-L1 creates feedforward antitumor responses to overcome checkpoint blockade resistance. Nature Communications. 9: 4586. PMID 30389912 DOI: 10.1038/S41467-018-06890-Y |
0.512 |
|
| 2018 |
Evans JD, Morris LK, Zhang H, Cao S, Liu X, Mara KC, Stish BJ, Davis BJ, Mansfield AS, Dronca RS, Iott Cnp MJ, Kwon ED, Foote RL, Olivier KR, Dong H, et al. Prospective Immunophenotyping of CD8 T-cells and Associated Clinical Outcomes of Patients with Oligometastatic Prostate Cancer Treated with Metastasis-Directed SBRT. International Journal of Radiation Oncology, Biology, Physics. PMID 30205124 DOI: 10.1016/J.Ijrobp.2018.09.001 |
0.39 |
|
| 2018 |
Chen G, Huang AC, Zhang W, Zhang G, Wu M, Xu W, Yu Z, Yang J, Wang B, Sun H, Xia H, Man Q, Zhong W, Antelo LF, Wu B, ... ... Dong H, et al. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature. PMID 30089911 DOI: 10.1038/S41586-018-0392-8 |
0.493 |
|
| 2018 |
Chakrabarti S, Dong H, Paripati HR, Ross HJ, Yoon HH. First Report of Dramatic Tumor Responses with Ramucirumab and Paclitaxel After Progression on Pembrolizumab in Two Cases of Metastatic Gastroesophageal Adenocarcinoma. The Oncologist. PMID 29674442 DOI: 10.1634/theoncologist.2017-0561 |
0.358 |
|
| 2018 |
Yan Y, Cao S, Liu X, Harrington SM, Bindeman WE, Adjei AA, Jang JS, Jen J, Li Y, Chanana P, Mansfield AS, Park SS, Markovic SN, Dronca RS, Dong H. CX3CR1 identifies PD-1 therapy-responsive CD8+ T cells that withstand chemotherapy during cancer chemoimmunotherapy. Jci Insight. 3. PMID 29669928 DOI: 10.1172/Jci.Insight.97828 |
0.561 |
|
| 2018 |
Tang H, Liang Y, Anders RA, Taube JM, Qiu X, Mulgaonkar A, Liu X, Harrington SM, Guo J, Xin Y, Xiong Y, Nham K, Silvers W, Hao G, Sun X, ... ... Dong H, et al. PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regression. The Journal of Clinical Investigation. PMID 29337303 DOI: 10.1172/Jci96061 |
0.417 |
|
| 2018 |
Bhindi B, Lohse CM, Cheville JC, Mason R, Tollefson MK, Harrington S, Dong H, Parker AS, Boorjian SA, Thompson RH, Leibovich BC. Creation of a tissue expression biomarker-augmented prognostic model for patients with metastatic renal cell carcinoma. Journal of Clinical Oncology. 36: 703-703. DOI: 10.1200/Jco.2018.36.6_Suppl.703 |
0.473 |
|
| 2018 |
Duma N, Paludo J, Enninga EA, Yadav S, Vera-Aguilera J, Kottschade LA, Dong H, Adjei AA, Dronca RS. Sex differences in tolerability to Anti-PD1 therapy: Are we all equal? Journal of Clinical Oncology. 36: 9547-9547. DOI: 10.1200/Jco.2018.36.15_Suppl.9547 |
0.361 |
|
| 2018 |
Wang Y, Sinha S, Dong H, Secreto C, Call T, Parikh SA, Leis JF, Rech K, Feldman AL, Kenderian S, Kay NE, Ansell SM, He R, Ding W. Distinct immune signatures in chronic lymphocytic leukemia (CLL) and Richter’s syndrome (RS). Journal of Clinical Oncology. 36: 7524-7524. DOI: 10.1200/Jco.2018.36.15_Suppl.7524 |
0.412 |
|
| 2018 |
Dronca RS, Mansfield A, Liu X, Harrington S, Enninga E, Markovic S, Kottschade L, Mcwilliams R, Block M, Nevala W, Thompson M, Dong H. Abstract A38: Blood-based T cell biomarkers and soluble PD-L1 predict responses and immune-related toxicity to PD-1 blockade in melanoma and lung cancer Cancer Immunology Research. 6. DOI: 10.1158/2326-6074.Tumimm17-A38 |
0.555 |
|
| 2018 |
Mansfield AS, Peikert T, Smadbeck JB, Udell JB, Kosari F, Murphy SJ, Ren H, Serla VV, Klein JLS, Karagouga G, Harris FR, Sosa C, Johnson SH, Nevala W, Markovic SN, ... ... Dong H, et al. Abstract 5726: Rearrangement-related peptides with neoantigenic potential in malignant pleural mesothelioma Cancer Research. 78: 5726-5726. DOI: 10.1158/1538-7445.Am2018-5726 |
0.311 |
|
| 2018 |
Lowerison M, Cepeda M, Liu C, Fedyshyn Y, Joshi V, Shah P, Cheville J, Leibovich B, Boorjian S, Dong H, Leong H. PD57-07 RAPID PATIENT DERIVED XENOGRAFTS THAT CONSIDER TUMOR HETEROGENEITY FOR PREDICTION OF CANCER IMMUNOTHERAPY RESPONSES IN METASTATIC RENAL CELL CARCINOMA Journal of Urology. 199. DOI: 10.1016/J.JURO.2018.02.2651 |
0.346 |
|
| 2018 |
Duma N, Azzouqa A, Yadav S, Hoversten K, Reed C, Sitek A, Enninga E, Paludo J, Aguilera JV, Lou Y, Molina J, Leventakos K, Kottschade L, Dong H, Mansfield A, et al. P1.01-17 Immune-Related Adverse Events in Patients with Metastatic Non-Small Cell Lung Cancer: Sex Differences and Response to Therapy Journal of Thoracic Oncology. 13. DOI: 10.1016/J.Jtho.2018.08.573 |
0.326 |
|
| 2018 |
Evans JD, Morris LK, Dong H, Cao S, Liu X, Mara K, Stish BJ, Davis BJ, Olivier K, Mansfield AS, Dronca RS, Iott MJ, Kwon ED, Foote RL, Park SS. Prospective Immunophenotyping of CD8+ T-cells and Associated Clinical Outcomes of Patients with Oligometastatic Prostate Cancer Treated with Metastasis-Directed Stereotactic Body Radiation Therapy International Journal of Radiation Oncology Biology Physics. 102. DOI: 10.1016/J.Ijrobp.2018.06.351 |
0.371 |
|
| 2017 |
Dong H, Yan Y, Dronca RS, Markovic SN. A T cell equation as a conceptual model of T cell responses for maximizing the efficacy of cancer immunotherapy. Soj Immunology. 5: 1-5. PMID 29629436 DOI: 10.15226/2372-0948/5/1/00155 |
0.302 |
|
| 2017 |
Pavelko KD, Bell MP, Harrington SM, Dong H. B7-H1 Influences the Accumulation of Virus-Specific Tissue Resident Memory T Cells in the Central Nervous System. Frontiers in Immunology. 8: 1532. PMID 29170671 DOI: 10.3389/fimmu.2017.01532 |
0.49 |
|
| 2017 |
Terra SBSP, Mansfield AS, Dong H, Peikert T, Roden AC. Temporal and spatial heterogeneity of programmed cell death 1-Ligand 1 expression in malignant mesothelioma. Oncoimmunology. 6: e1356146. PMID 29147606 DOI: 10.1080/2162402X.2017.1356146 |
0.43 |
|
| 2017 |
Lehrke HD, Graham RP, McWilliams RR, Lam-Himlin DM, Smyrk TC, Jenkins S, Dong H, Zhang L. Undifferentiated Pancreatic Carcinomas Display Enrichment for Frequency and Extent of PD-L1 Expression by Tumor Cells. American Journal of Clinical Pathology. PMID 29069274 DOI: 10.1093/Ajcp/Aqx092 |
0.445 |
|
| 2017 |
Gibbons Johnson RM, Dong H. Functional Expression of Programmed Death-Ligand 1 (B7-H1) by Immune Cells and Tumor Cells. Frontiers in Immunology. 8: 961. PMID 28848559 DOI: 10.3389/Fimmu.2017.00961 |
0.563 |
|
| 2017 |
Zhou G, Sprengers D, Boor PPC, Doukas M, Schutz H, Mancham S, Pedroza-Gonzalez A, Polak WG, de Jonge J, Gaspersz M, Dong H, Thielemans K, Pan Q, IJzermans JNM, Bruno MJ, et al. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-infiltrating T cells in Hepatocellular Carcinomas. Gastroenterology. PMID 28648905 DOI: 10.1053/J.Gastro.2017.06.017 |
0.507 |
|
| 2017 |
Xue J, Chen C, Qi M, Huang Y, Wang L, Gao Y, Dong H, Ling K. Type Iγ phosphatidylinositol phosphate kinase regulates PD-L1 expression by activating NF-κB. Oncotarget. PMID 28465490 DOI: 10.18632/Oncotarget.17123 |
0.498 |
|
| 2017 |
Ding W, LaPlant BR, Call TG, Parikh SA, Leis JF, He R, Shanafelt TD, Sinha S, Le-Rademacher J, Feldman AL, Habermann TM, Witzig TE, Wiseman GA, Lin Y, Asmus E, ... ... Dong H, et al. Pembrolizumab in patients with chronic lymphocytic leukemia with Richter's transformation and relapsed CLL. Blood. PMID 28424162 DOI: 10.1182/Blood-2017-02-765685 |
0.413 |
|
| 2017 |
Ni X, Song Q, Cassady K, Deng R, Jin H, Zhang M, Dong H, Forman S, Martin PJ, Chen YZ, Wang J, Zeng D. PD-L1 interacts with CD80 to regulate graft-versus-leukemia activity of donor CD8+ T cells. The Journal of Clinical Investigation. PMID 28414296 DOI: 10.1172/Jci91138 |
0.426 |
|
| 2017 |
Yan Y, Dronca RS, Liu X, Markovic S, Dong H. Effect of paclitaxel and carboplatin on tumor-reactive T cells and the efficacy of PD-1 blockade. Journal of Clinical Oncology. 35: 65-65. DOI: 10.1200/Jco.2017.35.7_Suppl.65 |
0.489 |
|
| 2017 |
Dronca RS, Harrington S, Jegapragasan M, Kottschade LA, Nevala WK, Enninga EA, Markovic S, Dong H. Association of soluble PD-L1 (sPD-L1) with decreased survival in metastatic melanoma. Journal of Clinical Oncology. 35: 4-4. DOI: 10.1200/Jco.2017.35.7_Suppl.4 |
0.445 |
|
| 2017 |
Dronca RS, Mansfield AS, Liu X, Harrington S, Enninga EA, Kottschade LA, Koo CW, McWilliams RR, Block MS, Nevala WK, Markovic S, Dong H. Bim and soluble PD-L1 (sPD-L1) as predictive biomarkers of response to anti-PD-1 therapy in patients with melanoma and lung carcinoma. Journal of Clinical Oncology. 35: 11534-11534. DOI: 10.1200/Jco.2017.35.15_Suppl.11534 |
0.421 |
|
| 2017 |
Mansfield A, Liu X, Cao S, Bindeman W, Yin P, Till L, Harrington S, Dong H. 1195PCompromised efficacy of PD-L1 blockade therapy in axenic (germ-free) mice with syngeneic tumors Annals of Oncology. 28. DOI: 10.1093/Annonc/Mdx376.058 |
0.42 |
|
| 2017 |
Mansfield A, Ren H, Sutor S, Dronca R, Park S, Markovic S, Nevala W, Jen J, Aubry MC, Dong H. OA 13.07 Contraction of T Cell Clonality in Lung Cancer Metastases Journal of Thoracic Oncology. 12. DOI: 10.1016/J.Jtho.2017.09.406 |
0.35 |
|
| 2016 |
Sharma V, Dong H, Kwon E, Karnes RJ. Positive Pelvic Lymph Nodes in Prostate Cancer Harbor Immune Suppressor Cells To Impair Tumor-reactive T Cells. European Urology Focus. PMID 28753790 DOI: 10.1016/j.euf.2016.09.003 |
0.459 |
|
| 2016 |
Liu X, Wu X, Cao S, Harrington SM, Yin P, Mansfield AS, Dong H. B7-H1 antibodies lose antitumor activity due to activation of p38 MAPK that leads to apoptosis of tumor-reactive CD8(+) T cells. Scientific Reports. 6: 36722. PMID 27824138 DOI: 10.1038/Srep36722 |
0.576 |
|
| 2016 |
Dronca RS, Mansfield AS, Park SS, Dong H. BCL-2-interacting mediator of cell death (Bim) is a novel biomarker for response to anti-PD-1 therapy in patients with advanced melanoma. Immunotherapy. PMID 27784186 DOI: 10.2217/Imt-2016-0100 |
0.424 |
|
| 2016 |
Yin P, Liu X, Mansfield AS, Harrington SM, Li Y, Yan Y, Dong H. CpG-induced antitumor immunity requires IL-12 in expansion of effector cells and down-regulation of PD-1. Oncotarget. PMID 27602959 DOI: 10.18632/Oncotarget.11833 |
0.504 |
|
| 2016 |
Dronca RS, Liu X, Harrington SM, Chen L, Cao S, Kottschade LA, McWilliams RR, Block MS, Nevala WK, Thompson MA, Mansfield AS, Park SS, Markovic SN, Dong H. T cell Bim levels reflect responses to anti-PD-1 cancer therapy. Jci Insight. 1. PMID 27182556 DOI: 10.1172/Jci.Insight.86014 |
0.533 |
|
| 2016 |
Mansfield AS, Dong H. Implications of programmed cell death 1 ligand 1 heterogeneity in the selection of patients with non-small cell lung cancer to receive immunotherapy. Clinical Pharmacology and Therapeutics. PMID 26916808 DOI: 10.1002/Cpt.360 |
0.453 |
|
| 2016 |
Dong H, Karnes J. Regional lymph nodes involved by prostate cancer harbor immune suppressor cells that impair the function of tumor-reactive T cells. Journal of Clinical Oncology. 34. DOI: 10.1200/Jco.2016.34.15_Suppl.E16551 |
0.373 |
|
| 2016 |
Ding W, Le-Rademacher J, Call TG, Parikh SA, Leis JF, Shanafelt TD, He R, Habermann TM, Lin Y, Laplant BR, Feldman AL, Witzig TE, Chanan-Khan AA, Asmus E, Van Dyke DL, ... ... Dong H, et al. PD-1 Blockade with Pembrolizumab in Relapsed CLL Including Richter's Transformation: An Updated Report from a Phase 2 Trial (MC1485) Blood. 128: 4392-4392. DOI: 10.1182/Blood.V128.22.4392.4392 |
0.369 |
|
| 2016 |
Cao S, Liu X, Wu X, Mansfield A, Dong H. Abstract A131: B7-H1 identifies tumor-reactive effector CD8 T cells susceptible of deletion by agonist PD-L1 antibodies Cancer Immunology Research. 4. DOI: 10.1158/2326-6066.Imm2016-A131 |
0.615 |
|
| 2016 |
Enninga EA, Nevala W, Creedon D, Flotte T, Dong H, Markovic S. Shared immunoregulatory properties of galectin-9 and PD-L1 in pregnant women and patients with stage IV melanoma Placenta. 45: 86-87. DOI: 10.1016/J.Placenta.2016.06.090 |
0.359 |
|
| 2015 |
Karyampudi L, Lamichhane P, Krempski J, Kalli KR, Behrens MD, Vargas DM, Hartmann LC, Janco JM, Dong H, Hedin KE, Dietz AB, Goode EL, Knutson KL. PD-1 blunts the function of ovarian tumor-infiltrating dendritic cells by inactivating NF-KappaB. Cancer Research. PMID 26567141 DOI: 10.1158/0008-5472.Can-15-0748 |
0.43 |
|
| 2015 |
Park SS, Dong H, Liu X, Harrington SM, Krco CJ, Grams MP, Mansfield AS, Furutani KM, Olivier KR, Kwon ED. PD-1 Restrains Radiotherapy-Induced Abscopal Effect. Cancer Immunology Research. 3: 610-9. PMID 25701325 DOI: 10.1158/2326-6066.Cir-14-0138 |
0.478 |
|
| 2015 |
Dronca RS, Dong H. A gender factor in shaping T-cell immunity to melanoma. Frontiers in Oncology. 5: 8. PMID 25699234 DOI: 10.3389/Fonc.2015.00008 |
0.54 |
|
| 2015 |
Dronca RS, Markovic S, Kottschade LA, McWilliams RR, Block MS, Nevala WK, Thompson MA, Dong H. Bim as a predictive T-cell biomarker for response to anti-PD-1 therapy in metastatic melanoma (MM). Journal of Clinical Oncology. 33: 9013-9013. DOI: 10.1200/Jco.2015.33.15_Suppl.9013 |
0.516 |
|
| 2015 |
Dronca R, Liu X, Lisa K, Mcwilliams R, Markovic S, Dong H. Bim and PD-1 identify effector CD8 T cells responsive to anti-PD-1 therapy in metastatic melanoma patients Journal For Immunotherapy of Cancer. 3. DOI: 10.1186/2051-1426-3-S2-P298 |
0.58 |
|
| 2015 |
Ding W, Dong H, Call TG, Shanafelt TD, Parikh SA, Leis JF, Laplant BR, He R, Witzig TE, Lin Y, Chanan-Khan A, Bowen DA, Conte M, Habermann TM, Viswanatha D, et al. PD-1 Blockade with Pembrolizumab (MK-3475) in Relapsed/Refractory CLL Including Richter Transformation: An Early Efficacy Report from a Phase 2 Trial (MC1485) Blood. 126: 834-834. DOI: 10.1182/Blood.V126.23.834.834 |
0.421 |
|
| 2015 |
Park SS, Dong H, Harrington S, Grams M, Mansfield AS, Furutani KM, Olivier K, Kwon ED. CD11ahighCD8+ T Cell Phenotype Identifies Tumor Specific Effector Cells Whose Frequency and Function Are Enhanced by RT International Journal of Radiation Oncology Biology Physics. 93. DOI: 10.1016/J.Ijrobp.2015.07.230 |
0.426 |
|
| 2014 |
Mansfield AS, Roden AC, Peikert T, Sheinin YM, Harrington SM, Krco CJ, Dong H, Kwon ED. B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 9: 1036-40. PMID 24926549 DOI: 10.1097/Jto.0000000000000177 |
0.449 |
|
| 2014 |
Gibbons RM, Liu X, Harrington SM, Krco CJ, Kwon ED, Dong H. B7-H1 signaling is integrated during CD8(+) T cell priming and restrains effector differentiation. Cancer Immunology, Immunotherapy : Cii. 63: 859-67. PMID 24893858 DOI: 10.1007/s00262-014-1563-6 |
0.478 |
|
| 2014 |
Dong H, Zhao W, Krco CJ, Markovic S, Mansfield AS, Olivier KR, Park SS, Kwon ED. A novel method for identifying downstream signals in tumor-reactive T cells following PD-1 engagement and monitoring endogenous tumor immunity and immunotherapy. Journal of Clinical Oncology. 32: 3049-3049. DOI: 10.1200/Jco.2014.32.15_Suppl.3049 |
0.548 |
|
| 2014 |
Orzechowski A, Dong H. Abstract 5026: B7-H1 confers tumor chemoresistance by regulating MAPK/ERK activation Cancer Research. 74: 5026-5026. DOI: 10.1158/1538-7445.Am2014-5026 |
0.489 |
|
| 2014 |
Zhao W, Dong H. Abstract 2552: T cell apoptosis signaling biomarker of PD-1 engagement in cancer patients Cancer Research. 74: 2552-2552. DOI: 10.1158/1538-7445.Am2014-2552 |
0.584 |
|
| 2014 |
Park SS, Dong H, Zhao W, Grams MP, Liu X, Harrington SM, Furutani KM, Krco CJ, Olivier KR, Markovic SN, Kwon ED. PD-1 Blockade Enhances Radiation Therapy-Induced Abscopal Effect International Journal of Radiation Oncology Biology Physics. 90. DOI: 10.1016/J.Ijrobp.2014.05.201 |
0.361 |
|
| 2013 |
Liu X, Gibbons RM, Harrington SM, Krco CJ, Markovic SN, Kwon ED, Dong H. Endogenous tumor-reactive CD8(+) T cells are differentiated effector cells expressing high levels of CD11a and PD-1 but are unable to control tumor growth. Oncoimmunology. 2: e23972. PMID 23894697 DOI: 10.4161/Onci.23972 |
0.564 |
|
| 2013 |
Tamura H, Ishibashi M, Yamashita T, Tanosaki S, Okuyama N, Kondo A, Hyodo H, Shinya E, Takahashi H, Dong H, Tamada K, Chen L, Dan K, Ogata K. Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma. Leukemia. 27: 464-72. PMID 22828443 DOI: 10.1038/Leu.2012.213 |
0.512 |
|
| 2013 |
Dong H, Markovic S, Krco CJ, Kwon ED. A novel method to identify and monitor endogenous tumor-reactive T cells by high expression of CD11a (LFA-1) and PD-1 (CD279) as immunologic readout for evaluating the efficacy of PD-1 blockade. Journal of Clinical Oncology. 31: 3037-3037. DOI: 10.1200/Jco.2013.31.15_Suppl.3037 |
0.571 |
|
| 2012 |
Gibbons RM, Liu X, Pulko V, Harrington SM, Krco CJ, Kwon ED, Dong H. B7-H1 limits the entry of effector CD8(+) T cells to the memory pool by upregulating Bim. Oncoimmunology. 1: 1061-1073. PMID 23170254 DOI: 10.4161/Onci.20850 |
0.795 |
|
| 2012 |
Frigola X, Inman BA, Krco CJ, Liu X, Harrington SM, Bulur PA, Dietz AB, Dong H, Kwon ED. Soluble B7-H1: differences in production between dendritic cells and T cells. Immunology Letters. 142: 78-82. PMID 22138406 DOI: 10.1016/J.Imlet.2011.11.001 |
0.547 |
|
| 2011 |
Pulko V, Harris KJ, Liu X, Gibbons RM, Harrington SM, Krco CJ, Kwon ED, Dong H. B7-h1 expressed by activated CD8 T cells is essential for their survival. Journal of Immunology (Baltimore, Md. : 1950). 187: 5606-14. PMID 22025548 DOI: 10.4049/Jimmunol.1003976 |
0.783 |
|
| 2011 |
Krempski J, Karyampudi L, Behrens MD, Erskine CL, Hartmann L, Dong H, Goode EL, Kalli KR, Knutson KL. Tumor-infiltrating programmed death receptor-1+ dendritic cells mediate immune suppression in ovarian cancer. Journal of Immunology (Baltimore, Md. : 1950). 186: 6905-13. PMID 21551365 DOI: 10.4049/Jimmunol.1100274 |
0.601 |
|
| 2011 |
Frigola X, Inman BA, Lohse CM, Krco CJ, Cheville JC, Thompson RH, Leibovich B, Blute ML, Dong H, Kwon ED. Identification of a soluble form of B7-H1 that retains immunosuppressive activity and is associated with aggressive renal cell carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 1915-23. PMID 21355078 DOI: 10.1158/1078-0432.Ccr-10-0250 |
0.443 |
|
| 2010 |
Archibald DJ, Neff BA, Voss SG, Splinter PL, Driscoll CL, Link MJ, Dong H, Kwon ED. B7-H1 expression in vestibular schwannomas. Otology & Neurotology : Official Publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology. 31: 991-7. PMID 20601920 DOI: 10.1097/Mao.0B013E3181E40E4F |
0.395 |
|
| 2010 |
Nguyen LT, Ciric B, Ure DR, Zhou B, Tamada K, Tseng SY, Shin T, Chen L, Dong H, Kyle RA, Rodriguez M, Pease LR. Retraction: Naturally occurring human IgM antibody that binds B7-DC and potentiates T cell stimulation by dendritic cells. Journal of Immunology (Baltimore, Md. : 1950). 184: 6552. PMID 20483792 DOI: 10.4049/Jimmunol.1090031 |
0.392 |
|
| 2010 |
Mirza N, Duque MA, Dominguez AL, Schrum AG, Dong H, Lustgarten J. B7-H1 expression on old CD8+ T cells negatively regulates the activation of immune responses in aged animals. Journal of Immunology (Baltimore, Md. : 1950). 184: 5466-74. PMID 20375308 DOI: 10.4049/Jimmunol.0903561 |
0.455 |
|
| 2009 |
Pulko V, Liu X, Krco CJ, Harris KJ, Frigola X, Kwon ED, Dong H. TLR3-stimulated dendritic cells up-regulate B7-H1 expression and influence the magnitude of CD8 T cell responses to tumor vaccination. Journal of Immunology (Baltimore, Md. : 1950). 183: 3634-41. PMID 19710456 DOI: 10.4049/Jimmunol.0900974 |
0.775 |
|
| 2009 |
Wilcox RA, Feldman AL, Wada DA, Yang ZZ, Comfere NI, Dong H, Kwon ED, Novak AJ, Markovic SN, Pittelkow MR, Witzig TE, Ansell SM. B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders. Blood. 114: 2149-58. PMID 19597183 DOI: 10.1182/Blood-2009-04-216671 |
0.605 |
|
| 2009 |
Gong AY, Zhou R, Hu G, Li X, Splinter PL, O'Hara SP, LaRusso NF, Soukup GA, Dong H, Chen XM. MicroRNA-513 regulates B7-H1 translation and is involved in IFN-gamma-induced B7-H1 expression in cholangiocytes. Journal of Immunology (Baltimore, Md. : 1950). 182: 1325-33. PMID 19155478 DOI: 10.4049/Jimmunol.182.3.1325 |
0.414 |
|
| 2009 |
Archibald DJ, Driscoll CLW, Neff BA, Voss SG, Link MJ, Dong H, Kwon ED. B7 homolog 1 expression in vestibular schwannomas Otolaryngology-Head and Neck Surgery. 141. DOI: 10.1016/J.Otohns.2009.06.227 |
0.345 |
|
| 2008 |
Crispen PL, Sheinin Y, Roth TJ, Lohse CM, Kuntz SM, Frigola X, Thompson RH, Boorjian SA, Dong H, Leibovich BC, Blute ML, Kwon ED. Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 5150-7. PMID 18694993 DOI: 10.1158/1078-0432.Ccr-08-0536 |
0.489 |
|
| 2008 |
Dong H, Fulko V, Harris K, Frigola X, Liu X. The reverse signals of costimulatory molecule B7-H1 negatively regulate memory CD8 T cell function in tumor immunity The Faseb Journal. 22: 523-523. DOI: 10.1096/Fasebj.22.2_Supplement.523 |
0.513 |
|
| 2008 |
Tollefson MK, Leibovich BC, Cheville JC, Baro XF, Dong H, Kwon ED. CD-4+ CD-25hi REGULATORY T-CELLS IN THE REGIONAL LYMPH NODES OF PATIENTS WITH UROTHELIAL CARCINOMA The Journal of Urology. 179: 314-314. DOI: 10.1016/S0022-5347(08)60919-2 |
0.385 |
|
| 2007 |
Webster WS, Thompson RH, Harris KJ, Frigola X, Kuntz S, Inman BA, Dong H. Targeting molecular and cellular inhibitory mechanisms for improvement of antitumor memory responses reactivated by tumor cell vaccine. Journal of Immunology (Baltimore, Md. : 1950). 179: 2860-9. PMID 17709500 DOI: 10.4049/jimmunol.179.5.2860 |
0.409 |
|
| 2007 |
Siddiqui SA, Frigola X, Bonne-Annee S, Mercader M, Kuntz SM, Krambeck AE, Sengupta S, Dong H, Cheville JC, Lohse CM, Krco CJ, Webster WS, Leibovich BC, Blute ML, Knutson KL, et al. Tumor-infiltrating Foxp3-CD4+CD25+ T cells predict poor survival in renal cell carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 2075-81. PMID 17404089 DOI: 10.1158/1078-0432.Ccr-06-2139 |
0.477 |
|
| 2007 |
Thompson RH, Dong H, Lohse CM, Leibovich BC, Blute ML, Cheville JC, Kwon ED. PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 1757-61. PMID 17363529 DOI: 10.1158/1078-0432.Ccr-06-2599 |
0.551 |
|
| 2007 |
Krambeck AE, Dong H, Thompson RH, Kuntz SM, Lohse CM, Leibovich BC, Blute ML, Sebo TJ, Cheville JC, Parker AS, Kwon ED. Survivin and b7-h1 are collaborative predictors of survival and represent potential therapeutic targets for patients with renal cell carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 1749-56. PMID 17363528 DOI: 10.1158/1078-0432.CCR-06-2129 |
0.479 |
|
| 2007 |
Inman BA, Sebo TJ, Frigola X, Dong H, Bergstralh EJ, Frank I, Fradet Y, Lacombe L, Kwon ED. PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression. Cancer. 109: 1499-505. PMID 17340590 DOI: 10.1016/S0022-5347(18)31107-8 |
0.514 |
|
| 2007 |
Inman BA, Frigola X, Dong H, Kwon ED. Costimulation, coinhibition and cancer. Current Cancer Drug Targets. 7: 15-30. PMID 17305475 DOI: 10.2174/156800907780006878 |
0.492 |
|
| 2007 |
Thompson RH, Dong H, Kwon ED. Implications of B7-H1 expression in clear cell carcinoma of the kidney for prognostication and therapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 709s-715s. PMID 17255298 DOI: 10.1158/1078-0432.Ccr-06-1868 |
0.541 |
|
| 2007 |
Tollefson MK, Leibovich BC, Cheville JC, Dong H, Kwon ED. MP-04.07: CD-4+ CD-25+ regulatory T-cells in the tumor draining lymph nodes of patients with urothelial carcinoma Urology. 70: 60. DOI: 10.1016/J.Urology.2007.06.235 |
0.418 |
|
| 2006 |
Zhang X, Dong H, Lin W, Voss S, Hinkley L, Westergren M, Tian G, Berry D, Lewellen D, Vile RG, Chen L, Farber DL, Strome SE. Human bone marrow: a reservoir for "enhanced effector memory" CD8+ T cells with potent recall function. Journal of Immunology (Baltimore, Md. : 1950). 177: 6730-7. PMID 17082586 DOI: 10.4049/Jimmunol.177.10.6730 |
0.433 |
|
| 2006 |
Dong H, Chen X. Immunoregulatory role of B7-H1 in chronicity of inflammatory responses. Cellular & Molecular Immunology. 3: 179-87. PMID 16893498 |
0.382 |
|
| 2006 |
Krambeck AE, Thompson RH, Dong H, Lohse CM, Park ES, Kuntz SM, Leibovich BC, Blute ML, Cheville JC, Kwon ED. B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. Proceedings of the National Academy of Sciences of the United States of America. 103: 10391-6. PMID 16798883 DOI: 10.1073/Pnas.0600937103 |
0.495 |
|
| 2006 |
Webster WS, Lohse CM, Thompson RH, Dong H, Frigola X, Dicks DL, Sengupta S, Frank I, Leibovich BC, Blute ML, Cheville JC, Kwon ED. Mononuclear cell infiltration in clear-cell renal cell carcinoma independently predicts patient survival. Cancer. 107: 46-53. PMID 16708355 DOI: 10.1002/Cncr.21951 |
0.378 |
|
| 2006 |
Thompson RH, Kuntz SM, Leibovich BC, Dong H, Lohse CM, Webster WS, Sengupta S, Frank I, Parker AS, Zincke H, Blute ML, Sebo TJ, Cheville JC, Kwon ED. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Research. 66: 3381-5. PMID 16585157 DOI: 10.1158/0008-5472.Can-05-4303 |
0.493 |
|
| 2006 |
Webster WS, Lohse CM, Thompson RH, Dong H, Frigola X, Dicks D, Sengupta S, Frank I, Leibovich BC, Blute ML, Cheville JC, Kwon ED. 746: Mononuclear Cell Infiltration in Clear Cell Renal Cell Carcinoma Independently Predicts Patient Survival The Journal of Urology. 175: 242-243. DOI: 10.1016/S0022-5347(18)32982-3 |
0.341 |
|
| 2006 |
Webster WS, Dong H, Thompson RH, Sengupta S, Lohse CM, Leibovich BC, Blute ML, Kwon ED. 399: Complete Tumor Regression of Established Murine Renal Cell Carcinoma Following CD4+ T Cell Depletion and B7-H1 Blockade The Journal of Urology. 175: 130-130. DOI: 10.1016/S0022-5347(18)32655-7 |
0.524 |
|
| 2006 |
Krambeck AE, Parks E, Lohse CM, Cheville JC, Dong H, Leibovich BC, Blute ML, Kwon ED. 387: The Immunomodulatory Protein B7-H4 Expression in Renal Cell Carcinoma Patients: A Strong Predictor of Cancer Progression and Survival The Journal of Urology. 175: 127-127. DOI: 10.1016/S0022-5347(18)32643-0 |
0.403 |
|
| 2006 |
Thompson RH, Leibovich BC, Dong H, Lohse CM, Webster WS, Zincke H, Blute ML, Sebo TJ, Cheville JC, Kwon ED. 386: Tumor B7-H1 is Associated with Poor Prognosis in Renal Cell Carcinoma Patients with Long Term Follow-Up The Journal of Urology. 175: 126-126. DOI: 10.1016/S0022-5347(18)32642-9 |
0.409 |
|
| 2006 |
Thompson RH, Dong H, Lohse CM, Cheville JC, Kwon ED. 385: PD-1 Expression by Tumor Infiltrating Lymphocytes is Associated with Poor Prognosis in Renal Cell Carcinoma Patients The Journal of Urology. 175: 126-126. DOI: 10.1016/S0022-5347(18)32641-7 |
0.468 |
|
| 2005 |
Thompson RH, Gillett MD, Cheville JC, Lohse CM, Dong H, Webster WS, Chen L, Zincke H, Blute ML, Leibovich BC, Kwon ED. Costimulatory molecule B7-H1 in primary and metastatic clear cell renal cell carcinoma. Cancer. 104: 2084-91. PMID 16208700 DOI: 10.1002/cncr.21470 |
0.38 |
|
| 2005 |
Thompson RH, Webster WS, Cheville JC, Lohse CM, Dong H, Leibovich BC, Kuntz SM, Sengupta S, Kwon ED, Blute ML. B7-H1 glycoprotein blockade: a novel strategy to enhance immunotherapy in patients with renal cell carcinoma. Urology. 66: 10-4. PMID 16194701 DOI: 10.1016/J.Urology.2005.06.010 |
0.493 |
|
| 2005 |
Tamura H, Dan K, Tamada K, Nakamura K, Shioi Y, Hyodo H, Wang SD, Dong H, Chen L, Ogata K. Expression of functional B7-H2 and B7.2 costimulatory molecules and their prognostic implications in de novo acute myeloid leukemia. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 5708-17. PMID 16115907 DOI: 10.1158/1078-0432.Ccr-04-2672 |
0.455 |
|
| 2005 |
Hirano F, Kaneko K, Tamura H, Dong H, Wang S, Ichikawa M, Rietz C, Flies DB, Lau JS, Zhu G, Tamada K, Chen L. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Research. 65: 1089-96. PMID 15705911 |
0.478 |
|
| 2005 |
Thompson RH, Gillett MD, Cheville JC, Lohse CM, Dong H, Webster WS, Krejci KG, Lobo JR, Sengupta S, Chen L, Zincke H, Blute ML, Strome SE, Leibovich BC, Kwon ED. 618: Costimulatory B7-H1 In Renal Cell Carcinoma Patients: Indicator of Tumor Aggressiveness and Potential Therapeutic Target The Journal of Urology. 173: 169-169. DOI: 10.1016/S0022-5347(18)34858-4 |
0.425 |
|
| 2004 |
Thompson RH, Gillett MD, Cheville JC, Lohse CM, Dong H, Webster WS, Krejci KG, Lobo JR, Sengupta S, Chen L, Zincke H, Blute ML, Strome SE, Leibovich BC, Kwon ED. Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proceedings of the National Academy of Sciences of the United States of America. 101: 17174-9. PMID 15569934 DOI: 10.1073/pnas.0406351101 |
0.439 |
|
| 2004 |
Roden AC, Moser MT, Tri SD, Mercader M, Kuntz SM, Dong H, Hurwitz AA, McKean DJ, Celis E, Leibovich BC, Allison JP, Kwon ED. Augmentation of T cell levels and responses induced by androgen deprivation. Journal of Immunology (Baltimore, Md. : 1950). 173: 6098-108. PMID 15528346 DOI: 10.4049/Jimmunol.173.10.6098 |
0.431 |
|
| 2004 |
Luo L, Chapoval AI, Flies DB, Zhu G, Hirano F, Wang S, Lau JS, Dong H, Tamada K, Flies AS, Liu Y, Chen L. B7-H3 enhances tumor immunity in vivo by costimulating rapid clonal expansion of antigen-specific CD8+ cytolytic T cells. Journal of Immunology (Baltimore, Md. : 1950). 173: 5445-50. PMID 15494491 DOI: 10.4049/Jimmunol.173.9.5445 |
0.561 |
|
| 2004 |
Dong H, Zhu G, Tamada K, Flies DB, van Deursen JM, Chen L. B7-H1 determines accumulation and deletion of intrahepatic CD8(+) T lymphocytes. Immunity. 20: 327-36. PMID 15030776 DOI: 10.1016/S1074-7613(04)00050-0 |
0.464 |
|
| 2003 |
Tamura H, Ogata K, Dong H, Chen L. Immunology of B7-H1 and its roles in human diseases. International Journal of Hematology. 78: 321-8. PMID 14686489 DOI: 10.1007/Bf02983556 |
0.486 |
|
| 2003 |
Strome SE, Dong H, Tamura H, Voss SG, Flies DB, Tamada K, Salomao D, Cheville J, Hirano F, Lin W, Kasperbauer JL, Ballman KV, Chen L. B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Research. 63: 6501-5. PMID 14559843 |
0.438 |
|
| 2003 |
Dong H, Chen L. B7-H1 pathway and its role in the evasion of tumor immunity. Journal of Molecular Medicine (Berlin, Germany). 81: 281-7. PMID 12721664 DOI: 10.1007/S00109-003-0430-2 |
0.558 |
|
| 2003 |
Wang S, Bajorath J, Flies DB, Dong H, Honjo T, Chen L. Molecular modeling and functional mapping of B7-H1 and B7-DC uncouple costimulatory function from PD-1 interaction. The Journal of Experimental Medicine. 197: 1083-91. PMID 12719480 DOI: 10.1084/Jem.20021752 |
0.51 |
|
| 2003 |
Curiel TJ, Wei S, Dong H, Alvarez X, Cheng P, Mottram P, Krzysiek R, Knutson KL, Daniel B, Zimmermann MC, David O, Burow M, Gordon A, Dhurandhar N, Myers L, et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nature Medicine. 9: 562-7. PMID 12704383 DOI: 10.1038/Nm863 |
0.537 |
|
| 2003 |
Dong H, Strome SE, Matteson EL, Moder KG, Flies DB, Zhu G, Tamura H, Driscoll CLW, Chen L. Costimulating aberrant T cell responses by B7-H1 autoantibodies in rheumatoid arthritis Journal of Clinical Investigation. 111: 363-370. PMID 12569162 DOI: 10.1172/Jci16015 |
0.429 |
|
| 2003 |
Trabattoni D, Saresella M, Biasin M, Boasso A, Piacentini L, Ferrante P, Dong H, Maserati R, Shearer GM, Chen L, Clerici M. B7-H1 is up-regulated in HIV infection and is a novel surrogate marker of disease progression. Blood. 101: 2514-20. PMID 12468426 DOI: 10.1182/Blood-2002-10-3065 |
0.338 |
|
| 2002 |
Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, Lennon VA, Celis E, Chen L. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nature Medicine. 8: 793-800. PMID 12091876 DOI: 10.1038/Nm730 |
0.583 |
|
| 2002 |
Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, Lennon VA, Celis E, Chen L. Erratum: Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion Nature Medicine. 8: 1039-1039. DOI: 10.1038/nm0902-1039c |
0.422 |
|
| 2001 |
Tamura H, Dong H, Zhu G, Sica GL, Flies DB, Tamada K, Chen L. B7-H1 costimulation preferentially enhances CD28-independent T-helper cell function. Blood. 97: 1809-16. PMID 11238124 DOI: 10.1182/Blood.V97.6.1809 |
0.541 |
|
| 2001 |
Chapoval AI, Ni J, Lau JS, Wilcox RA, Flies DB, Liu D, Dong H, Sica GL, Zhu G, Tamada K, Chen L. B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production. Nature Immunology. 2: 269-74. PMID 11224528 DOI: 10.1038/85339 |
0.558 |
|
| 2000 |
Wang S, Zhu G, Chapoval AI, Dong H, Tamada K, Ni J, Chen L. Costimulation of T cells by B7-H2, a B7-like molecule that binds ICOS Blood. 96: 2808-2813. DOI: 10.1182/Blood.V96.8.2808 |
0.498 |
|
| 1999 |
Dong H, Zhu G, Tamada K, Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nature Medicine. 5: 1365-9. PMID 10581077 DOI: 10.1038/70932 |
0.501 |
|
| 1994 |
Kimoto Y, Lee-Miyamoto M, Dong H, Takai S, Taguchi T. Treatment of malignant diseases using lectin-dependent lymphokine-activated killer cell-mediated cytotoxicity Japanese Journal of Clinical Immunology. 17: 188-198. DOI: 10.2177/Jsci.17.188 |
0.336 |
|
| Show low-probability matches. |